Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity
Status:
Terminated
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test whether ACULAR, a nonsteroidal anti-inflammatory eye
drop medication, can prevent the development of retinopathy of prematurity (ROP) and/ or
decrease its severity.In this study ACULAR will be compared to a placebo (artificial tear).
The hypothesis would be that ACULAR treatment will decrease the incidence of moderate to
severe ROP (grade II and above)by 50%.